The Global Health Body Issues Alert Over Severe Lack of Weight-Loss Jabs
Less than 10% of patients eligible to benefit from weight-loss injections including Wegovy can access them, states the global health agency as it publishes its first guidance on the therapies.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging broader and more equitable availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our latest guidelines affirms that excess weight is a long-term condition that can be addressed with thorough and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant barriers to broad availability to the injections that can aid individuals in losing significant weight, explains the agency.
Skinny Jab Shortage
Even under the current most optimistic case, the production of these medications might only reach around 100 million people – fewer than 10% of eligible patients, per the health organization.
The recommendation urges countries and companies to expand access, via measures like licensing agreements.
A patent on semaglutide – the core component of the drug Wegovy – is set to lapse in several nations in 2026.
The Way Weight-Loss Drugs Work
GLP-1 drugs mimick a body's own hormone to reduce digestion speed, curb appetite and increase feelings of fullness so people consume fewer calories.
People usually see weight reduction in the initial weeks of beginning the once-weekly jabs.
Studies suggests users may see weight return within a year of discontinuing the medication, as their usual hunger return.
Being above a healthy weight raises your likelihood for developing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight concerns people in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, per the WHO.
